A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Hengrui Medicine

Status and phase

Completed

Phase 2

Conditions

Non-Small-Cell Lung Cancer

Treatments

Drug: placebo

Drug: apatinib

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01270386

HENGRUI 20101219

Details and patient eligibility

About

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival compared with placebo in patients with advanced non-squamous and non-small cell lung cancer who failed two lines of chemotherapy.

Enrollment

136 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

≥ 18 and ≤ 70 years of age
Histologically or cytologic confirmed advanced non-squamous and non-small cell lung cancer.
At least one measurable lesion which has not received radiotherapy (larger than 10 mm in diameter by spiral CT scan)
Have failed for 2 lines of chemotherapy including EGFR-TKI.
ECOG performance scale 0 - 1.
Life expectancy of more than 3 months.
Duration from the last therapy is more than 6 weeks for nitroso or mitomycin
More than 4 weeks after operation or radiotherapy
More than 4 weeks for cytotoxic agents or tyrosine kinase inhibitors inhibitors
Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L, platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.25×the upper limit of normal(ULN), and serum transaminase≤2.5×the ULN (If liver metastases, serum transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min,
signed and dated informed consent.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.

Exclusion criteria

Squamous cell carcinoma (including adenosquamous carcinoma, undifferentiated carcinoma); small cell lung cancer (including small cell and non-small cell mixed lung cancer)
Pregnant or breastfeeding women
Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure
Any factors that influence the usage of oral administration
PT, APTT, TT, Fbg abnormal, Receiving the therapy of thrombolysis or anticoagulation.
Within 4 weeks before the first use of drugs, occurs pulmonary hemorrhage (≥ CTCAE class 2) or other parts' hemorrhage (≥ CTCAE class 3).
Long-term untreated wounds or fractures.
Within 6 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc.
Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5, with the purpose of prevention, the use of small doses of warfarin (1mg orally, once daily) or low-dose aspirin (between 80mg to 100mg daily) is allowed.
Abuse of alcohol or drugs
Less than 4 weeks from the last clinical trial
Treatment with VEGFR, PDGFR, sSRC-TKI before.
History of any second malignancies within 3 years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.